Table I.
Clinical characteristics and baseline demographics of the study population
| Characteristics | Patients n = 77 |
|---|---|
| Male, n (%) | 58 (75) |
| Female, n (%) | 18 (25) |
| Age, years, mean ± SD | 44 ± 15.6 |
| Duration of psoriasis, years, median (IQR) | 14.5 (7–26) |
| BMI, kg/m2, median (IQR) | 27.8 (24.2–30.4) |
| Patients with comorbidities, n (%) | 44 (57.1) |
| Patients with CMC, n | 42 |
| Obesity, n (%) | 14 (18.2) |
| Diabetes, n (%) | 8 (10.4) |
| Arterial hypertension, n (%) | 29 (37.7) |
| Dyslipidaemia, n (%) | 4 (5.2) |
| Psoriatic arthritis, n (%) | 1 (1.3) |
| Bio-naïve, n (%) | 47 (61) |
| Exposure to previous biologics, n (%) | 30 (39) |
| 1 previous biologic | 15 (50.0) |
| 2 or more previous biologics | 15 (50.0) |
| Previous biologics, n (%) | |
| Anti-TNF | 20 (26) |
| Anti-IL 12/23 | 8 (10.4) |
| Anti-IL 17 | 18 (23.4) |
| Baseline PASI <20 | 59 (76.6) |
| Baseline PASI ≥20 | 18 (23.4) |
BMI: body mass index; TNF: tumour necrosis factor; IL: interleukin; PASI: Psoriasis Area and Severity Index; SD: standard deviation; IQR: interquartile range.